Use of an rxr agonist in treating her2+ cancers
AssigneesIo Therapeutics, Inc., The University of Texas MD Anderson Cancer Center
InventorsMartin E. Sanders, Powel H. Brown, M.D., Ph.D.
Life of this patent
Estimating the term…
Abstract
The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
Claims20
A method of treating a patient with Her2+ breast cancer comprising administering a RXR agonist of Formula I,
- wherein R is H, or lower alkyl of 1 to 6 carbons;
- or a pharmaceutically-acceptable salt thereof, to the patient,
- wherein the patient has received, is receiving, or is scheduled to receive a Her2-targeted therapeutic antibody.
A method of treating a patient with Her2+ breast cancer undergoing treatment with a Her2-targeted therapeutic antibody, wherein there is evidence of therapeutic effect that is less than a complete response, comprising continuing treatment with the Her2-targeted therapeutic antibody and initiating treatment with a RXR agonist of Formula I,
- wherein R is H, or lower alkyl of 1 to 6 carbons;
- or a pharmaceutically-acceptable salt thereof.
(canceled)
10-20. (canceled)
Dependencies are inferred from the claim text.